Your new team At ING we have the bold ambition to create the most personal and impactful mobile led financial experience for our customers, while making a positive contribution to the society and the world we
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Integrated Risk (IR) provides a Group-wide view of ING’s risk profile, connecting governance, methodologies and risk insights to support senior and board-level decision-making. Within IR, Integrated Risk Oversight (IRO) focuses on oversight of credit risk models